Radiology Unit, A.O.U. San Luigi Gonzaga - Orbassano (To), Orbassano, TO, Italy.
Department of Oncology, University of Torino, Turin, Italy.
Eur Radiol. 2020 Aug;30(8):4496-4503. doi: 10.1007/s00330-020-06700-4. Epub 2020 Mar 19.
The acquisition of adequate tumor sample is required to verify primary tumor type and specific biomarkers and to assess response to therapy. Historically, invasive surgical procedures were the standard methods to acquire tumor samples until advancements in imaging and minimally invasive equipment facilitated the paradigm shift image-guided biopsy. Image-guided biopsy has improved sampling yield and minimized risk to the patient; however, there are still limitations, such as its invasive nature and its consequent limitations to longitudinal tumor monitoring. The next paradigm shift in sampling technique will need to address these issues to provide a more reliable and less invasive technique. Recently, liquid biopsy (LB) has emerged as a non-invasive alternative to tissue sampling. This technique relies on direct sampling of blood or other bodily fluids in contact with the tumor in order to collect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating RNAs-in particular microRNA (miRNAs). Clinical applications of LB involve different steps of cancer patient management including screening, detection of disease recurrence, and evaluation of acquired resistance. With any paradigm shift, old techniques are often relegated to a secondary option. Although image-guided biopsies may appear as a passive spectator on the rapid advancement of LB, the two techniques may well be codependent. Interventional radiology may be integral to directly sample the liquid surrounding or draining from the tumor. In addition, LB may help to correctly select the patients for image-guided loco-regional treatments, to determine its treatment endpoint, and to early detect recurrence. KEY POINTS: • Liquid biopsy is a novel technology with potential high impact in the management of patients undergoing image-guided procedures. • Interventional radiology procedures may increase liquid biopsy sensitivity through direct fluid sampling. • Liquid biopsy techniques may provide a venue for improving patients' selection and enhance outcomes of interventional loco-regional therapies performed by interventional radiologists.
获得足够的肿瘤样本是验证原发肿瘤类型和特定生物标志物并评估治疗反应的必要条件。历史上,侵入性手术是获取肿瘤样本的标准方法,直到影像学和微创设备的进步促进了图像引导活检的范式转变。图像引导活检提高了采样效率,并将患者的风险降至最低;然而,它仍然存在一些局限性,例如它的侵入性及其对肿瘤纵向监测的限制。采样技术的下一个范式转变将需要解决这些问题,以提供更可靠和微创的技术。最近,液体活检 (LB) 已成为组织采样的非侵入性替代方法。这种技术依赖于直接从与肿瘤接触的血液或其他体液中采样,以收集循环肿瘤 DNA(ctDNA)、循环肿瘤细胞(CTC)和循环 RNA,特别是 microRNA(miRNA)。LB 的临床应用涉及癌症患者管理的不同步骤,包括筛查、疾病复发的检测以及获得性耐药的评估。随着任何范式的转变,旧技术往往会被降级为次要选择。尽管图像引导活检可能看起来像是 LB 快速发展的被动旁观者,但这两种技术很可能是相互依存的。介入放射学可能是直接从肿瘤周围或引流的液体中取样的关键因素。此外,LB 可能有助于正确选择接受图像引导局部区域治疗的患者,确定其治疗终点,并早期检测复发。要点:
液体活检是一项具有潜在重大影响的新技术,可用于管理接受图像引导程序的患者。
介入放射学程序可以通过直接液体采样提高液体活检的灵敏度。
液体活检技术可以为改善患者选择提供途径,并增强介入放射科医生进行的介入局部区域治疗的结果。